ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1120

Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F

Siba Raychaudhuri1, Disha Chakraborty2, Christine Abria2 and Smriti K Raychaudhuri3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2Sacramento VA Medical Center, Mather, CA, 3Sacramento VA Medical Center, Davis, CA

Meeting: ACR Convergence 2025

Keywords: cytokines, Infection, innate immunity, neutrophils

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1088–1122) Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: IL-17 is primarily secreted by Th17 cells. The IL-17 family has 6 related cytokines (IL-17A to IL17F); IL-17A and IL-17F, being key proinflammatory mediators. IL-17A is known for its critical role in neutrophil-mediated immune defense. Notably, dual blockade of IL-17A/F has been associated with a higher risk of candidal infections compared to IL-17A inhibition alone. The objective of this study is to investigate the reason for increased risk of candidiasis linked to dual IL-17A/F blockade. Both IL-17A and IL-17F signal through IL-17RA/IL-17RC. This shared pathway suggests a synergistic role in neutrophil-mediated innate immunity; thus, inhibiting both may increase susceptibility to infections. Here we determined synergistic effects of IL-17A/IL-17F on (i) neutrophil chemotaxis and (ii) candidal killing.

Methods: Blood was collected from psoriatic arthritis (PsA) and osteoarthritis (OA) patients (n=12/each). Neutrophils were isolated using density gradient centrifugation; 1×10*6 cells were seeded into 5 µm pore Transwell inserts (upper chamber) in a 24-well plate. In the lower chambers rIL-17A, rIL-17F, with or without anti-IL-17A/F mab antibodies were added (100 ng/ml each, ThermoScientific). After 12 hours, the inserts were removed, and neutrophil migration was quantified by measuring the number of neutrophils in the lower chamber by MTT assay (optical density (OD) at 450nm, Millipore Sigma). To assess neutrophil phagocytic killing of candida, 0.25×10*6 Candida with the same cytokine/antibody conditions as above were added in the lower chamber and 1×10*6 neutrophils in the upper chamber. After 12 hours, migrated neutrophils in the lower chamber were lysed with pH11 H2O; rest of the living cells (Candida)were measured by MTT assay. Results are expressed in OD (Mean±SEM) of lower chamber cells.

Results: Neutrophils treated with rIL-17A (OD: 0.149±0.006), rIL-17F (OD: 0.362±0.007), and rIL-17A+rIL-17F (OD: 0.474±0.018) showed significantly higher chemotaxis (p< 0.001) compared to media only in PsA patients. Chemotaxis was also significantly higher with rIL-17A vs. rIL-17A+anti-IL17A mab (OD: 0.161±0.008, p< 0.001) and rIL-17F vs. rIL-17F+anti-IL-17F mab (OD: 0.160±0.019, p< 0.01). Notably, rIL-17A+rIL-17F induced greater chemotaxis compared to rIL-17A or rIL-17F (p< 0.001) and which could be effectively blocked by anti-IL17A/F (Fig-1). rIL-17A+rIL-17F driven neutrophil chemotaxis effectively killed and significantly reduced candida population (OD: 0.363±0.014) compared to rIL-17A (OD: 0.410±0.005) or rIL-17F (OD: 0.435±0.25)[p< 0.004; Fig-2].

Conclusion: This study reports a unique innate immune function of IL-17A and IL-17F, a synergistic enhancement of neutrophil chemotaxis, which could be effectively blocked by anti-IL17A and anti-IL17F mabs (Fig-1). Furthermore, IL-17A+IL-17F significantly reduced Candida survival by inducing neutrophil chemotaxis, which was neutralized by IL-17A/IL-17F mAbs, leading to increased survival of candida (Fig-2). These findings suggest that dual IL-17A/IL-17F blockade may increase the risk of candidal infections, highlighting the need for close monitoring for mucosal and systemic candidiasis in patients with these therapies.

Supporting image 1Figure 1: Comparison of neutrophil chemotaxis induced by rIL17A, rIL17F and anti rIL17A + rIL-17F. Both rIL17-A and rIL-17F induced chemotaxis of neutrophils; however combined rIL-17A + rIL-17F showed significantly higher neutrophil chemotaxis. Another intriguing observation was increased chemotaxis with rIL-17A/rIL17F on the neutrophils of psoriatic arthritis (PsA) compared to osteoarthritis (OA).

Supporting image 2Figure 2: Reduction of candida population as a result of significant neutrophil chemotaxis induced by rIL-17A + rIL-17F. The IL-17A/ILF mabs significantly reduced neutrophil chemotaxis (Fig-1A) resulting in higher candida survival.


Disclosures: S. Raychaudhuri: AbbVie, 5, Amgen, 2, Eli Lilly, 2, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sun Pharma, 5; D. Chakraborty: None; C. Abria: None; S. Raychaudhuri: None.

To cite this abstract in AMA style:

Raychaudhuri S, Chakraborty D, Abria C, Raychaudhuri S. Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/synergistic-effects-of-il-17f-and-il-17a-on-neutrophil-chemotaxis-increased-risk-of-candidiasis-with-dual-blockade-of-il-17a-and-il17-f/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synergistic-effects-of-il-17f-and-il-17a-on-neutrophil-chemotaxis-increased-risk-of-candidiasis-with-dual-blockade-of-il-17a-and-il17-f/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology